Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06439914
PHASE1

First-in-human Study of Interferon-y PET Imaging to Assess Response to Immunotherapy

Sponsor: Nerissa T. Viola

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to investigate the use of \[89Zr\]Zr-DFO-emapalumab as an IFN-γ PET imaging agent to detect lesions and response to therapy among treatment-naïve non-small cell lung cancer (NSCLC) patients. PET scans following the imaging agent will be completed prior to and about 30 days after starting immunotherapy.

Official title: IFN-y PET Imaging: Bench to Bedside

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2026-03-09

Completion Date

2029-06

Last Updated

2026-03-11

Healthy Volunteers

No

Interventions

DRUG

[89Zr]Zr-DFO-emapalumab

Radiotracer \[89Zr\]Zr-DFO-emapalumab administration followed by 3 PET Scans (day 0, day 1 and day 3-5) within 14 days of starting immunotherapy and repeated once 25-45 days after immunotherapy started

Locations (1)

Karmanos Cancer Institute

Detroit, Michigan, United States